Patents by Inventor Naoya KAMEYAMA
Naoya KAMEYAMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230204613Abstract: Disclosed is a specimen analysis method for analyzing a specimen regarding a plurality of measurement items, the specimen analysis method comprising: measuring a first measurement item and a second measurement item on the basis of a measurement order; executing a process related to a time difference between a measurement of the first measurement item and a measurement of the second measurement item; and obtaining a calculation value from a measurement value of the first measurement item and a measurement value of the second measurement item.Type: ApplicationFiled: December 16, 2022Publication date: June 29, 2023Applicant: Sysmex CorporationInventors: Naoya Kameyama, Tomoyuki Nishida, Yasuhiro Takeuchi, Takayuki Arai, Masahiro Miura
-
Publication number: 20180371100Abstract: There is provided an anti-human CRTH2 antibody which has desired activity by recognizing and binding to a specific human CRTH2; the antibody fragment; DNA which encodes the amino acid sequence of the antibody; a vector which comprises the DNA; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of Th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.Type: ApplicationFiled: September 7, 2018Publication date: December 27, 2018Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Naoya Kameyama, Munetoshi Ando, Shinya Ogawa, Kazuki Okada
-
Patent number: 10100120Abstract: There is provided an anti-human CRTH2 antibody which has desired activity by recognizing and binding to a specific human CRTH2; the antibody fragment; DNA which encodes the amino acid sequence of the antibody; a vector which comprises the DNA; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of Th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.Type: GrantFiled: February 16, 2018Date of Patent: October 16, 2018Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Naoya Kameyama, Munetoshi Ando, Shinya Ogawa, Kazuki Okada
-
Publication number: 20180222994Abstract: There is provided an anti-human CRTH2 antibody which has desired activity by recognizing and binding to a specific human CRTH2; the antibody fragment; DNA which encodes the amino acid sequence of the antibody; a vector which comprises the DNA; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of Th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.Type: ApplicationFiled: February 16, 2018Publication date: August 9, 2018Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Kazuki Okada, Naoya Kameyama, Munetoshi Ando, Shinya Ogawa
-
Patent number: 9938349Abstract: There is provided an anti-human CRTH2 antibody which has desired activity by recognizing and binding to a specific human CRTH2; the antibody fragment; DNA which encodes the amino acid sequence of the antibody; a vector which comprises the DNA; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of Th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.Type: GrantFiled: November 3, 2016Date of Patent: April 10, 2018Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Naoya Kameyama, Munetoshi Ando, Shinya Ogawa, Kazuki Okada
-
Patent number: 9695237Abstract: The present invention provides an anti-human FOLR1 antibody against diseases associated with human FOLR1-expressing cells, which specifically recognizes and binds to an amino acid sequence of human FOLR1 or a conformational structure thereof and also has a high effector activity such as antibody-dependent cellular cytotoxicity activity (ADCC activity). The present invention can provide a monoclonal antibody which specifically recognizes and binds to the amino acid sequence of human FOLR1 or the conformational structure thereof and also has ADCC activity and CDC activity, or an antibody fragment thereof, a DNA encoding the antibody, a vector comprising the DNA, a transformant obtained by introducing the vector, a method for producing the antibody or the antibody fragment thereof using the transformant, and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment as an active ingredient.Type: GrantFiled: September 30, 2015Date of Patent: July 4, 2017Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Munetoshi Ando, Hiroshi Ando, Mariko Nakano, Naoya Kameyama, Tsuguo Kubota
-
Publication number: 20170121415Abstract: There is provided an anti-human CRTH2 antibody which has desired activity by recognizing and binding to a specific human CRTH2; the antibody fragment; DNA which encodes the amino acid sequence of the antibody; a vector which comprises the DNA; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of Th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.Type: ApplicationFiled: November 3, 2016Publication date: May 4, 2017Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Naoya KAMEYAMA, Munetoshi ANDO, Shinya OGAWA, Kazuki OKADA
-
Publication number: 20160060340Abstract: The present invention provides an anti-human FOLR1 antibody against diseases associated with human FOLR1-expressing cells, which specifically recognizes and binds to an amino acid sequence of human FOLR1 or a conformational structure thereof and also has a high effector activity such as antibody-dependent cellular cytotoxicity activity (ADCC activity). The present invention can provide a monoclonal antibody which specifically recognizes and binds to the amino acid sequence of human FOLR1 or the conformational structure thereof and also has ADCC activity and CDC activity, or an antibody fragment thereof, a DNA encoding the antibody, a vector comprising the DNA, a transformant obtained by introducing the vector, a method for producing the antibody or the antibody fragment thereof using the transformant, and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment as an active ingredient.Type: ApplicationFiled: September 30, 2015Publication date: March 3, 2016Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Munetoshi ANDO, Hiroshi ANDO, Mariko NAKANO, Naoya KAMEYAMA, Tsuguo KUBOTA
-
Patent number: 9207238Abstract: The present invention provides an anti-human FOLR1 antibody against diseases associated with human FOLR1-expressing cells, which specifically recognizes and binds to an amino acid sequence of human FOLR1 or a conformational structure thereof and also has a high effector activity such as antibody-dependent cellular cytotoxicity activity (ADCC activity). The present invention can provide a monoclonal antibody which specifically recognizes and binds to the amino acid sequence of human FOLR1 or the conformational structure thereof and also has ADCC activity and CDC activity, or an antibody fragment thereof, a DNA encoding the antibody, a vector comprising the DNA, a transformant obtained by introducing the vector, a method for producing the antibody or the antibody fragment thereof using the transformant, and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment as an active ingredient.Type: GrantFiled: November 25, 2013Date of Patent: December 8, 2015Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Munetoshi Ando, Hiroshi Ando, Mariko Nakano, Naoya Kameyama, Tsuguo Kubota
-
Publication number: 20140205610Abstract: The present invention provides an anti-human FOLR1 antibody against diseases associated with human FOLR1-expressing cells, which specifically recognizes and binds to an amino acid sequence of human FOLR1 or a conformational structure thereof and also has a high effector activity such as antibody-dependent cellular cytotoxicity activity (ADCC activity). The present invention can provide a monoclonal antibody which specifically recognizes and binds to the amino acid sequence of human FOLR1 or the conformational structure thereof and also has ADCC activity and CDC activity, or an antibody fragment thereof, a DNA encoding the antibody, a vector comprising the DNA, a transformant obtained by introducing the vector, a method for producing the antibody or the antibody fragment thereof using the transformant, and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment as an active ingredient.Type: ApplicationFiled: November 25, 2013Publication date: July 24, 2014Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Munetoshi ANDO, Hiroshi ANDO, Mariko NAKANO, Naoya KAMEYAMA, Tsuguo KUBOTA